文献速递类风湿关节炎

1990-2020年全球、区域和国家类风湿关节炎疾病负担及2050年预测:2021年全球疾病负担研究的系统分析

Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.
PubMed 文献 · Lancet Rheumatol · 2023-09-25

该研究基于2021年全球疾病负担研究,采用贝叶斯元回归模型和死因集成模型,估算1990至2020年204个国家和地区的类风湿关节炎患病率、死亡率和伤残调整生命年,并预测至2050年。

要点

  • 2020年全球类风湿关节炎年龄标化患病率为每10万人208.8例,较1990年上升14.1%。
  • 女性年龄标化患病率高于男性,女性与男性比为2.45。
  • 2020年伤残损失健康寿命年占伤残调整生命年的76.4%,吸烟对伤残调整生命年的风险归因为7.1%。

核心结论

  • 过去三十年间全球类风湿关节炎死亡率下降,但年龄标化患病率和伤残损失健康寿命年上升,且病例数预计至2050年持续增加。
  • 作者认为需要改善全球范围内类风湿关节炎的早期诊断和治疗可及性,以减轻未来疾病负担。

研究设计与样本

  • 作为2021年全球疾病负担研究的一部分,使用贝叶斯元回归模型和基于人群研究及医疗索赔数据(98项患病率研究和25项发病率研究)估算1990至2020年204个国家和地区的类风湿关节炎患病率。
  • 死亡率采用死因集成模型从生命登记数据估算,伤残调整生命年由寿命损失年和伤残损失健康寿命年相加计算。
  • 采用逻辑回归以社会人口指数为预测因子预测至2050年类风湿关节炎患病率,再乘以预测人口估计数。

主要发现

  • 女性患病率更高,年龄标化女性与男性患病率比为2.45(2.40至2.47)。
  • 2020年年龄标化死亡率为每10万人0.47例(0.41至0.54),全球死亡38300例(33500至44000),较1990至2020年下降23.8%(17.5至29.3)。
  • 2020年伤残调整生命年计数为3060000(2320000至3860000),年龄标化伤残调整生命年率为每10万人36.4(27.6至45.9),伤残损失健康寿命年占伤残调整生命年的76.4%(68.3至81.0)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis is a chronic autoimmune inflammatory disease associated with disability and premature death. Up-to-date estimates of the burden of rheumatoid arthritis are required for health-care planning, resource allocation, and prevention. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we provide updated estimates of the prevalence of rheumatoid arthritis and its associated deaths and disability-adjusted life-years (DALYs) by age, sex, year, and location, with forecasted prevalence to 2050. METHODS: Rheumatoid arthritis prevalence was estimated in 204 countries and territories from 1990 to 2020 using Bayesian meta-regression models and data from population-based studies and medical claims data (98 prevalence and 25 incidence studies). Mortality was estimated from vital registration data with the Cause of Death Ensemble model (CODEm). Years of life lost (YLL) were calculated with use of standard GBD lifetables, and years lived with disability (YLDs) were estimated from prevalence, a meta-analysed distribution of rheumatoid arthritis severity, and disability weights. DALYs were calculated by summing YLLs and YLDs. Smoking was the only risk factor analysed. Rheumatoid arthritis prevalence was forecast to 2050 by logistic regression with Socio-Demographic Index as a predictor, then multiplying by projected population estimates. FINDINGS: In 2020, an estimated 17·6 million (95% uncertainty interval 15·8-20·3) people had rheumatoid arthritis worldwide. The age-standardised global prevalence rate was 208·8 cases (186·8-241·1) per 100 000 population, representing a 14·1% (12·7-15·4) increase since 1990. Prevalence was higher in females (age-standardised female-to-male prevalence ratio 2·45 [2·40-2·47]). The age-standardised death rate was 0·47 (0·41-0·54) per 100 000 population (38 300 global deaths [33 500-44 000]), a 23·8% (17·5-29·3) decrease from 1990 to 2020. The 2020 DALY count was 3 060 000 (2 320 000-3 860 000), with an age-standardised DALY rate of 36·4 (27·6-45·9) per 100 000 population. YLDs accounted for 76·4% (68·3-81·0) of DALYs. Smoking risk attribution for rheumatoid arthritis DALYs was 7·1% (3·6-10·3). We forecast that 31·7 million (25·8-39·0) individuals will be living with rheumatoid arthritis worldwide by 2050. INTERPRETATION: Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age-standardised prevalence rate and YLDs have increased over the same period, and the number of cases is projected to continue to increase to the year 2050. Improved access to early diagnosis and treatment of rheumatoid arthritis globally is required to reduce the future burden of the disease. FUNDING: Bill & Melinda Gates Foundation, Institute of Bone and Joint Research, and Global Alliance for Musculoskeletal Health.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023. PMID: 37795020. doi:10.1016/S2665-9913(23)00211-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。